PTGS2 and colorectal carcinoma: Three independent observational studies by Ng, Hua, and Friis indicated an increased survival for long-term, regular users of non-steroidal anti-inflammatory drugs (NSAIDS) after CRC diagnosis [5,6,7], of which specific PTGS2 inhibitors were found to be the most active.